Bloomington, IN, United States of America

Divyendu Singh

This inventor holds 1 USPTO granted patent. Top assignee: Indiana University. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Divyendu Singh

Introduction

Divyendu Singh is a notable inventor based in Bloomington, Indiana. He has made significant contributions to the field of immunology through his research and innovations. His work focuses on developing solutions that address critical health challenges.

Latest Patents

Divyendu Singh holds a patent for a peptide antagonist of LL-37. This invention is related to an antimicrobial peptide that plays multiple roles in both innate and adaptive immune responses. The identified peptide antagonists of LL-37 are designed to inhibit detrimental autoimmune inflammatory responses while retaining LL-37's antibacterial activity. This dual functionality highlights the potential of his invention in therapeutic applications.

Career Highlights

Divyendu Singh is affiliated with Indiana University, where he conducts his research and development work. His position at such a prestigious institution underscores his commitment to advancing scientific knowledge and innovation in the field of immunology.

Collaborations

Some of his notable coworkers include C Cheng Kao and Lani Rose San Mateo. Their collaborative efforts contribute to the advancement of research and innovation in their respective fields.

Conclusion

Divyendu Singh's work exemplifies the impact of innovative research in addressing health issues. His patent on the peptide antagonist of LL-37 showcases his dedication to improving immune responses and offers promising avenues for future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…